文献速递肺外科

原发性肺癌肺叶切除术后阿片类药物使用:Premier医院数据的倾向匹配分析

Postoperative opioid use after lobectomy for primary lung cancer: A propensity-matched analysis of Premier hospital data.
PubMed 文献 · J Thorac Cardiovasc Surg · 2020-05-16

该研究基于美国Premier医院数据库,采用倾向性评分匹配比较机器人肺叶切除(RL)与开胸及电视辅助胸腔镜(VATS)肺叶切除术后阿片类药物使用情况。结果显示RL组阿片类药物使用率、总剂量及日均剂量均低于开胸和VATS组,提示RL可能与更少的术后阿片类药物暴露相关。

要点

  • RL较开胸肺叶切除术后阿片使用率更低(87.2% vs 94.8%)。
  • RL较VATS肺叶切除术后阿片日均剂量更低(中位MEDD 28.8 vs 33.8)。
  • 需进一步研究早期阿片减量是否减少慢性阿片使用。

核心结论

  • 原发性肺癌行机器人肺叶切除的患者较开胸和VATS肺叶切除患者阿片类药物使用频率更低、总剂量和日均剂量更小。

研究设计与样本

  • 回顾性队列研究,数据来自美国Premier医院数据库,纳入2013年1月1日至2015年9月30日因原发性肺癌行肺叶切除的患者,采用倾向性评分匹配比较不同手术方式的阿片药物使用。

主要发现

  • 开胸与RL匹配队列各2061对,开胸组术后第1天至出院阿片使用率94.8% vs RL组87.2%(P < .001),总剂量中位MEDD 225.0 vs 100.0(P < .001),日均剂量中位MEDD 41.3 vs 30.0(P < .001)。
  • VATS与RL匹配队列各2142对,VATS组阿片使用率89.6% vs RL组87.0%(P = .008),总剂量中位MEDD 130.0 vs 100.0(P < .001),日均剂量中位MEDD 33.8 vs 28.8(P < .001)。

临床怎么用

  • 在肺癌肺叶切除术后疼痛管理中,可考虑优先采用机器人手术以减少阿片类药物使用,但需结合患者具体情况和中心技术条件。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate opioid administration after robotic lobectomy (RL) compared with video-assisted thoracic surgery (VATS) and open lobectomy in patients with lung cancer. METHODS: Patients undergoing lobectomy for primary lung cancer between January 1, 2013, and September 30, 2015, were identified from the US Premier Hospital Perspective Database. The primary outcome was the average daily dose of opioids received from postoperative day (POD) 1 until discharge. Opioid doses were converted to morphine equivalent daily doses (MEDDs). Propensity score matching was performed to balance patient, hospital, and surgeon characteristics when comparing opioid administration by surgical approach. RESULTS: The open versus RL cohort included 2061 matched pairs, and the VATS versus RL cohort included 2142 matched pairs. From POD 1 until discharge, the patients undergoing open lobectomy had a higher rate of opioid use compared with those undergoing RL (94.8% vs 87.2%; P < .001), with a higher total dose (median MEDD, 225.0 vs 100.0; P < .001) and average daily dose (median MEDD, 41.3 vs 30.0; P < .001). Similarly, from POD 1 until discharge, patients undergoing VATS lobectomy had a slightly higher rate of opioid use compared with those undergoing RL (89.6% vs 87.0%; P = .008), with a higher total dose (median MEDD, 130.0 vs 100.0; P < .001) and average daily dose (median MEDD, 33.8 vs 28.8; P < .001). CONCLUSIONS: Patients undergoing RL for primary lung cancer received opioids less frequently, and with lower total and average daily doses, compared with those undergoing VATS and open lobectomy. Studies are needed to determine whether early opioid dosage reductions translate into less chronic opioid use.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Rajaram R, Rice DC, Li Y, et al. Postoperative opioid use after lobectomy for primary lung cancer: A propensity-matched analysis of Premier hospital data. J Thorac Cardiovasc Surg. 2020. PMID: 32718706. doi:10.1016/j.jtcvs.2020.04.148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。